Elan: TYSABRI® 2006 News Archive

Elan Drug Technologies

Research &
Development

Investor Relations

Tysabri 2006 News Archive

Elan and Biogen Idec Submit Supplemental Biologics License Application to the FDA for the Approval of TYSABRI® as a Treatment for Crohn's Disease (12/15/2006)
TYSABRI(R) Maintained Remission in Patients with Moderate-to-Severe Crohn's Disease Treated for Longer Than Two Years According to Data Presented This Week (10/24/2006)
New Pharmacoeconomic Data on TYSABRI® Demonstrate Significant Reduction in Steroid Use and Hospitalizations in Patients with Multiple Sclerosis (10/6/2006)
Health Canada Grants Approval of TYSABRI(TM) (natalizumab) for the Treatment of Multiple Sclerosis Following Priority Review (10/4/2006)
New Data Presented at ECTRIMS Congress Show TYSABRI® Has Sustained Effect on Relapse Rate in Multiple Sclerosis Patients Treated for up to Three Years (9/29/2006)
New Data on TYSABRI® Presented at ECTRIMS Congress Demonstrate Significant Improvement in Cognitive Function in Patients with Multiple Sclerosis (9/28/2006)
Biogen Idec and Elan Announce Availability of TYSABRI® for the Treatment of Relapsing Forms of Multiple Sclerosis (7/24/06)
TYSABRI® Receives Approval in European Union for the Treatment of Relapsing Remitting Forms of Multiple Sclerosis (6/29/06)
FDA Approves the Reintroduction of TYSABRI® for the Treatment of Relapsing Forms of Multiple Sclerosis (5/6/06)
CHMP Issues Positive Opinion for TYSABRI® as a Treatment for Relapsing-Remitting Multiple Sclerosis (4/28/06)
New Data on TYSABRI® Demonstrate Significant Effects on Health-Related Quality of Life Measures in Patients with Multiple Sclerosis (4/6/06)
Biogen Idec and Elan Announce Re-Initiation of TYSABRI® Clinical Trial Dosing in Multiple Sclerosis (3/29/2006)
Biogen Idec and Elan Announce That FDA Will Extend Regulatory Review Period for the Reintroduction of TYSABRI® for Multiple Sclerosis(3/22/2006)
FDA Advisory Committee Unanimously Recommends Reintroduction of TYSABRI® for the Treatment of Relapsing Forms of Multiple Sclerosis(3/8/2006)
TYSABRI® Two-Year Phase III Multiple Sclerosis Clinical Trial Results and Safety Evaluation Published in New England Journal of Medicine; TYSABRI Currently Under Review with U.S. and European Regulatory Authorities (3/1/2006)
Elan Announces the Suspension of Trading of Its Shares Commencing March 7, 2006 For Up to Two Days; Suspension of Trading Due to Two Day FDA Advisory Committee Meeting to Review Tysabri (2/28/2006)
TYSABRI® Multiple Sclerosis Clinical Trial Hold Lifted by FDA; Biogen Idec and Elan to Resume Clinical Trial Dosing in MS(2/15/2006)
Biogen Idec and Elan Announce Notification of FDA Advisory Committee Meeting to Review TYSABRI® for the Treatment of Multiple Sclerosis (1/23/06)

Copyright © 2001- 2004 Elan Corporation, plc, Dublin, Ireland. All rights reserved. | Privacy Policy | Terms of use